Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04019262 · ClinicalTrials.gov registry record · Phase 1
Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma
A Phase 1 study of Glioblastoma, sponsored by John Flickinger.
- Active
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT04019262 is a Phase 1 study of Glioblastoma that is active but no longer recruiting, run by John Flickinger. The registered enrollment target is 2 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04019262, a Phase 1 study of Glioblastoma, is active but no longer recruiting, sponsored by John Flickinger.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, randomized, open-label, exploratory trial of temozolomide-based chemo-radiotherapy which compares two widely used established radiation schedules with either 40 Gy in 15 fractions or 25 Gy in 5 fractions with concurrent temozolomide for both schedules in patients with glioblastoma.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Temozolomide Oral Product
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center, Radiation Oncology - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04019262
The ClinicalTrials.gov registry entry for NCT04019262 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (98% lower). The listed sponsor is John Flickinger, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT04019262 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04019262 about?
NCT04019262 is a clinical study titled "Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma". This is a prospective, randomized, open-label, exploratory trial of temozolomide-based chemo-radiotherapy which compares two widely used established radiation schedules with either 40 Gy in 15 fractions or 25 Gy in 5 fractions with concurrent temozolomide for both schedules in patients with glioblas...
What is the current status of trial NCT04019262?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2021-12-14. Estimated completion is 2027-07.
What conditions does trial NCT04019262 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT04019262?
The interventions under investigation include: Radiation Therapy (RADIATION), Temozolomide Oral Product (DRUG).
Who is sponsoring clinical trial NCT04019262?
This trial is sponsored by John Flickinger, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04019262 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.